HomeGUTS • NASDAQ
add
Fractyl Health Inc
Previous close
$1.48
Day range
$1.48 - $1.57
Year range
$0.83 - $3.03
Market cap
215.16M USD
Avg Volume
1.85M
P/E ratio
-
Dividend yield
-
Primary exchange
NASDAQ
Market news
Financials
Income Statement
Revenue
Net income
| (USD) | Sep 2025info | Y/Y change |
|---|---|---|
Revenue | — | — |
Operating expense | 22.69M | -4.65% |
Net income | -45.60M | -96.79% |
Net profit margin | — | — |
Earnings per share | -0.71 | -65.66% |
EBITDA | -22.40M | 5.01% |
Effective tax rate | — | — |
Balance Sheet
Total assets
Total liabilities
| (USD) | Sep 2025info | Y/Y change |
|---|---|---|
Cash and short-term investments | 77.66M | -8.28% |
Total assets | 114.27M | -9.97% |
Total liabilities | 117.45M | 53.32% |
Total equity | -3.18M | — |
Shares outstanding | 137.04M | — |
Price to book | -74.00 | — |
Return on assets | -64.37% | — |
Return on capital | -110.69% | — |
Cash Flow
Net change in cash
| (USD) | Sep 2025info | Y/Y change |
|---|---|---|
Net income | -45.60M | -96.79% |
Cash from operations | -22.71M | -25.92% |
Cash from investing | -8.00K | 96.24% |
Cash from financing | 78.09M | 48,102.47% |
Net change in cash | 55.37M | 406.06% |
Free cash flow | -13.10M | -33.30% |
About
Fractyl Health is a Burlington, Massachusetts-based healthcare company focused on metabolic diseases like obesity and type 2 diabetes. The company developed Revita, an outpatient endoscopic procedure to modify duodenal dysfunction, and Rejuva, a gene therapy platform in preclinical development to enable the pancreas to produce glucagon-like peptide-1. Wikipedia
Founded
2010
Headquarters
Website
Employees
101
